Welcome to our Enriched Treatment Pathway – an expert-led practical and evidence-based tool designed help you to provide optimal management of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1RAs).

You have immediate access to expert opinion and the latest data and evidence, with practical guidance on how to incorporate learning and knowledge into your practice.

Suitable for: Primary care practitioners and diabetes specialists, including any healthcare professional involved in the management of people with type 2 diabetes.

The treatment pathway is available in English, French, Spanish and German.

The pathway was last updated in December 2021.

Endorsed by Primary Care Diabetes

Program Director Melanie Davies introduces this practical and evidence-based pathway. How will it help you? Watch now to find out more and how you can use it to inform and guide your practice.

Educational grant

This program has been made possible with an educational grant from Novo Nordisk A/S.

Contact us

Springer Healthcare IME
Email: IME@springer.com
Address: The Campus, 4 Crinan Street
London, N1 9XW, UK

Professor Melanie J Davies

Melanie J Davies is Professor of Diabetes Medicine at the University of Leicester and an Honorary Consultant Diabetologist at the University Hospitals of Leicester NHS Trust. She is based in the Diabetes Research Centre, University of Leicester, and is also the Co-Director of the Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust.

Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes. She is a National Institute for Health Research Senior Investigator Emeritus and Director of the NIHR Leicester Biomedical Research Centre. Professor Davies is the Principal Investigator on a number of large global studies in the field of diabetes, obesity, physical activity, sedentary behaviour and cardiovascular disease and co-chair of ADA EASD’s consensus report on type 2 diabetes management.

Professor Davies has published over 550 original articles and has over £60m of grant funding. She was awarded the CBE (Commander of the Most Excellent Order of the British Empire) in the 2016 New Year Honours List for services to diabetes research.


Professor Davies has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen, an advisory board member for Lexicon, Servier and Gilead Sciences Ltd, and as a speaker for Napp Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International Inc.

She has received grants in support of investigator and investigator-initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, AstraZeneca and Janssen.